Search results for "Cancer biomarkers"
showing 3 items of 13 documents
Proteomic Strategies and their Application in Cancer Research
2006
The understanding of carcinogenesis and tumor progression on a molecular basis needs a detailed study of proteins as effector molecules and as critical components of the multiple interconnected signaling pathways that drive the neoplastic phenotype. Thus, the proteomic approach represents a powerful tool for the challenge of the post-genomic era. The term “cancer proteome” refers to the collection of proteins expressed by a given cancer cell and should be considered as a highly dynamic entity within the cell, which affects a variety of cellular activities. The emerging proteomic analysis platforms including 2D-PAGE, mass spectrometry technologies, and protein microarrays represent powerful…
Leptin and Its Receptor are Overexpressed in Brain Tumors and Correlate with the Degree of Malignancy
2009
Although leptin and its receptor (ObR) have emerged as important cancer biomarkers, the role of the leptin system in brain tumor development remains unknown. We screened 87 human brain tumor biopsies using immunohistochemistry and detected leptin and ObR in 55.2% and 60.9% cases, respectively. In contrast, leptin and ObR were absent in 14 samples of normal brain tissue. The presence of leptin correlated with ObR with overall concordance 80.5%. The leptin/ObR system was highly expressed in glioblastomas and anaplastic astrocytomas, while lower expression of both markers was noted in low-grade astrocytomas and gangliogliomas. The association between leptin/ObR and the degree of tumor malignan…
Lateral flow assays towards point-of-care cancer detection: A review of current progress and future trends
2020
Abstract Cancer is one of the main causes of mortality and morbidity worldwide. However, its early non-invasive detection via quantification of appropriate biomarkers can significantly reduce mortality, enhance survival, and save treatment costs. Lateral flow test strips (LFTS) are nowadays considered as the most attractive point-of-care devices for healthcare applications. However, the quantification of cancer biomarkers in body fluids suffers from some challenges including i) the necessity for multiplex analysis, ii) the development of sensitive detection systems, iii) to overcome the analysis of complex samples, at the same time, it should keep the quality assurance criteria for an accur…